Hepatocyte Growth Factor – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) – Pipeline Review, H1 2020’, provides in depth analysis on Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Cardiovascular, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Hematological Disorders, Metabolic Disorders and Respiratory under development targeting Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)

– The report reviews Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics and enlists all their major and minor projects

– The report assesses Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AnGes Inc

Athira Pharma Inc

Beijing SH Bio-Tech Corp

Helixmith Co Ltd

i2 Pharmaceuticals Inc

Kringle Pharma Inc

Minerva Biotechnologies Corp

Molecular Partners AG

Yichang Humanwell Pharmaceutical Co Ltd

Yooyoung Pharm Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Overview

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Companies Involved in Therapeutics Development

AnGes Inc

Athira Pharma Inc

Beijing SH Bio-Tech Corp

Helixmith Co Ltd

i2 Pharmaceuticals Inc

Kringle Pharma Inc

Minerva Biotechnologies Corp

Molecular Partners AG

Yichang Humanwell Pharmaceutical Co Ltd

Yooyoung Pharm Co Ltd

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Drug Profiles

Ad-HGF - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

beperminogene perplasmid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

donaperminogene seltoplasmid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate HGF for Critical Limb Ischemia and Chronic Post-Operative Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to activate HGF for Lung Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate HGF for Neuro Muscular Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to activate HGF for Peripheral Artery Occlusive Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KP-100IT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-0250 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDX-1017 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NK-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-186 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-188 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YYB-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Dormant Products

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Discontinued Products

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Product Development Milestones

Featured News & Press Releases

Feb 04, 2020: AnGes, Inc. initiated Phase 2b study in the U.S. in patients with lower limb ischemic ulcers

Dec 27, 2019: Molecular Partners receives orphan drug designation for MP0250 for multiple myeloma

Dec 20, 2019: Genopis, plasmid DNA manufacturer in San Diego, to Launch GMP contract manufacturing business

Dec 12, 2019: Molecular Partners provides update on its Multiple Myeloma drug candidate MP-0250 at R&D Day

Dec 09, 2019: Athira Pharma presents positive data for NDX-1017 in Alzheimer's patients at 2019 clinical trials on Alzheimer's disease (CTAD) conference

Dec 07, 2019: Molecular Partners presents updated results of MP0250 in patients with Relapsed/Refractory Multiple Myeloma (MM) at American Society of Hematology Annual Meeting

Nov 20, 2019: Athira Pharma to present phase 1 data for NDX-1017 in oral presentation at 2019 clinical trials on Alzheimer's Disease (CTAD) Conference

Oct 07, 2019: Helixmith shows long-term safety and efficacy of VM202 for painful DPN patients in DPN phase 3-1b extension study

Oct 02, 2019: Athira Pharma Announces Completion of Phase 1b Clinical Trial of NDX-1017 in Alzheimers Patients

Sep 23, 2019: Helixmith: Topline results of DPN Phase III study

Sep 04, 2019: Notice regarding the launch of Collategene intramuscular injection 4 mg, an HGF gene therapy product

Aug 02, 2019: Helixmith unveils results for neuromuscular disease treatment

Jul 16, 2019: Athira Pharma presents preliminary results from phase 1 trial of NDX-1017 at Alzheimer's Association International Conference 2019 (AAIC)

May 27, 2019: Yooyoung Pharmaceutical: YYB101 -- refractory solid tumor treatment

May 01, 2019: Athira Pharma announces appointment of Dr. Hans J. Moebius as chief medical officer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indications, H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by AnGes Inc, H1 2020

Pipeline by Athira Pharma Inc, H1 2020

Pipeline by Beijing SH Bio-Tech Corp, H1 2020

Pipeline by Helixmith Co Ltd, H1 2020

Pipeline by i2 Pharmaceuticals Inc, H1 2020

Pipeline by Kringle Pharma Inc, H1 2020

Pipeline by Minerva Biotechnologies Corp, H1 2020

Pipeline by Molecular Partners AG, H1 2020

Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, H1 2020

Pipeline by Yooyoung Pharm Co Ltd, H1 2020

Dormant Products, H1 2020

Dormant Products, H1 2020 (Contd..1), H1 2020

Dormant Products, H1 2020 (Contd..2), H1 2020

Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports